Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
As scintigraphy with [(111)In-DTPA(0)]octreotide has become a standard technique in analysing somatostatin receptor-receptor positive lesions such as neuroendocrine tumours, a logical next step is peptide receptor radionuclide therapy (PRRT). Initial studies on PRRT were performed with high doses of [(111)In-DTPA(0)]octreotide, and recently other radionuclides coupled to other somatostatin analogues have been used for this purpose. However, the dose delivered to the kidney is a major dose-limiting factor. Amino acid solutions have previously been used to reduce renal uptake of radioactivity, but these solutions have some disadvantages, i.e. their hyperosmolarity and their propensity to cause vomiting and metabolic changes. In this study we tested various amino acid solutions in patients receiving [(111)In-DTPA(0)]octreotide PRRT in order to assess their safety and their capacity to inhibit the renal uptake of radioactivity. Patients served as their own non-infused control. Renal radioactivity at 24 h following the injection of [(111)In-DTPA(0)]octreotide was inhibited by (1) a commercially available amino acid solution (AA) (21%+/-14%, P<0.02), (2) by 25 g (17%+/-9%, P<0.04), 50 g (15%+/-13%, P<0.04) or 75 g of lysine (44%+/-11%, P<0.001) and (3) by a combination of 25 g of lysine plus 25 g of arginine (LysArg) (33%+/-23%, P<0.01). Fluid infusion alone (500, 1,000 or 2,000 ml of saline/glucose) did not change renal uptake of radioactivity. In patients studied with 75 g of lys…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“of which competitive inhibition of proximal tubular reabsorption by pretreatment with positively charged amino acids (arginine and lysine) has achieved a renal dose reduction of approximately 50% and is widely adopted in clinical practice ( 64 , 65 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [64]
Citations
Cites
Tolerance of normal tissue to therapeutic irradiation
Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488
Gibril, F., Reynolds, J. C., Doppman, J. L., Chen, C. C., Venzon, D. J., Termanini, B., Weber, H. C., Stewart, C. A., & Jensen, R. T. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00005 · Cited by 440
Valkema, R., de Jong, M., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Lugtenburg, P. J., de Jong, F. H., Christiansen, A., Kam, B. L. R., de Herder, W. W., et al. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc/2002.31025 · Cited by 435
Self-citationYttrium-90 DOTATOC: first clinical results
Otte, A., Herrmann, R., Heppeler, A., Behe, M., Jermann, E., Powell, P., Maecke, H. R., & Muller, J. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050476 · Cited by 420
Peptide receptor imaging and therapy.
Kwekkeboom, D. J., Krenning, E. P., & de Jong, M. (2000) · PubMed · Cited by 330
Self-citationBehr, T. M., Goldenberg, D. M., & Becker, W. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050216 · Cited by 274
Mogensen, C. E., & Sølling, K. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517709101835 · Cited by 233
Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
Paganelli, G., Zoboli, S., Cremonesi, M., Bodei, L., Ferrari, M., Grana, C., Bartolomei, M., Orsi, F., De Cicco, C., Mäcke, H. R., et al. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100490 · Cited by 206
Behr, T. M., Sharkey, R. M., Juweid, M. E., Blumenthal, R. D., Dunn, R. M., Griffiths, G. L., Bair, H. J., Wolf, F., Becker, W. S., & Goldenberg, D. M. (1995) · PubMed · Cited by 176
Bakker, W. H., Krenning, E. P., Reubi, J.-C., Breeman, W. A. P., Setyono-Han, B., de Jong, M., Kooij, P. P. M., Bruns, C., van Hagen, P. M., Marbach, P., et al. (1991) · Life Sciences · doi:10.1016/0024-3205(91)90053-e · Cited by 174
Self-citationEnd-stage renal disease after treatment with 90 Y-DOTATOC
Cybulla, M., Weiner, S. M., & Otte, A. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100599 · Cited by 154
Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue
Hammond, P., Wade, A., Gwilliam, M., Peters, A., Myers, M., Gilbey, S., Bloom, Sr., & Calam, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.266 · Cited by 131
Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo.
de Jong, M., Rolleman, E. J., Bernard, B. F., Visser, T. J., Bakker, W. H., Breeman, W. A., & Krenning, E. P. (1996) · PubMed · Cited by 130
Self-citationA new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy
Moll, S., Nickeleit, V., Mueller‐Brand, J., Brunner, F. P., Maëcke, H. R., & Mihatsch, M. J. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80135-9 · Cited by 120
Duncan, J. R., Stephenson, M. T., Wu, H. P., & Anderson, C. J. (1997) · PubMed · Cited by 107
Life-Threatening Hyperkalemia Induced by Arginine
Bushinsky, D. A., & GENNARI, F. J. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-89-5-632 · Cited by 91
Angiotensin II receptor antagonists in the treatment and prevention of radiation nephropathy
Cohen, J. (1998) · International Journal of Radiation Biology · doi:10.1080/095530098142257 · Cited by 51
Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy
Perazella, M. A., & Biswas, P. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70234-9 · Cited by 38
Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma
Stoffel, M., Pollok, M., Fries, J. G., & Baldamus, C. A. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.5.1082 · Cited by 31
The risk of pronounced hyperkalaemia after arginine infusion in the diabetic subject.
MASSARA, F., Cagliero, E., BISBOCCI, D., Passarino, G., Carta, Q., & Gm, M. (1981) · PubMed · Cited by 14
Arginine-induced hypophosphatemia and hyperkaliemia in man.
MASSARA, F., Martelli, S., Ghigo, E., Camanni, F., & Gm, M. (1979) · PubMed · Cited by 8
Sartori, S., Nielsen, I., Pennacchio, G., Pazzi, P., & Trevisani, L. (1991) · PubMed · Cited by 4
Metabolic effects of amino acids (AA) solutions infused for renal radioprotection.
Barone, R., Pauwels, S. A., Jamar, F., Camps, J., Smith, C., Kvols, L. K., & Krenning, E. (2000) · Journal of Nuclear Medicine · Cited by 3
Self-citation
Cited by
Zaknun, J. J., Bodei, L., Mueller-Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O’Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 818
Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours
Plöckinger, U., Rindi, G., Arnold, R., Eriksson, B., Krenning, E. P., de Herder, W. W., Goede, A., Caplin, M., Öberg, K., Reubi, J. C., et al. (2004) · Neuroendocrinology · doi:10.1159/000085237 · Cited by 477
Self-citationKratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R., Murphy, K., Haberkorn, U., & Morgenstern, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2857-9 · Cited by 407
Valkema, R., Pauwels, S. A., Kvols, L. K., Kwekkeboom, D. J., Jamar, F., de Jong, M., Barone, R., Walrand, S., Kooij, P. P. M., Bakker, W. H., et al. (2005) · PubMed · Cited by 379
Self-citationVegt, E., de Jong, M., Wetzels, J. F. M., Masereeuw, R., Melis, M., Oyen, W. J. G., Gotthardt, M., & Boerman, O. C. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.075101 · Cited by 334
Metadata
- Authors
- Rolleman, E., Valkema, R., de Jong, M., Kooij, P., & Krenning, E.
- Affiliations
- Erasmus MC (NL)
- Corresponding author
- Valkema, Roelf
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2003-01-01
- Volume
- 30
- Issue
- 1
- Pages
- 9-15
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2027511464
- Cited by
- 321
- References
- 24
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 8 · 2023: 10 · 2022: 11 · 2021: 27 · 2020: 19 · 2019: 11 · 2018: 15 · 2017: 14 · 2016: 12 · 2015: 9 · 2014: 17 · 2013: 14 · 2012: 17
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- lysine, L-arginine, amino acid infusion, peptide receptor radionuclide therapy, somatostatin receptors, neuroendocrine tumors, indium-111 octreotide, serum potassium, hyperkalemia, fluid infusion, safety and tolerability
- MeSH terms
- Arginine, Pentetic Acid, Female, Humans, Hyperkalemia, Infusions, Intravenous, Kidney, Lysine, Radionuclide Imaging, Vomiting, Octreotide, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Radiopharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.